Rates of depression and stress-related disorders rise among new fathers a year after birth, even though they have fewer ...

Is paternal postnatal depression delayed? New research finds a 30% increase in depression and stress diagnoses for fathers ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

People with depression tend to prefer carbohydrate-rich foods, according to a new study published in Psychological Medicine. The findings point toward the possibility of dietary therapies for ...

Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire Intra-Cellular Therapies, a company whose main asset has the potential to ...

Explore neuroscience breakthroughs reshaping treatments for Alzheimer’s, Parkinson’s, PTSD, and other brain disorders.